



UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE
United States Patent and Trademark Office
Address: COMMISSIONER OF PATENTS AND TRADEMARKS
Washington, D.C. 20231
www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
09/350,401	07/08/1999	ALESSANDRO SETTE	18623-013910	8008

7590

01/25/2002

TOWNSEND AND TOWNSEND AND CREW LLP
TWO EMBARCADERO CENTER 8TH FLOOR
SAN FRANCISCO, CA 941113834

EXAMINER

SCHWADRON, RONALD B

ART UNIT

PAPER NUMBER

1644

DATE MAILED: 01/25/2002

Please find below and/or attached an Office communication concerning this application or proceeding.



UNITED STATES DEPARTMENT OF COMMERCE
Patent and Trademark Office
COMMISSIONER OF PATENTS AND TRADEMARKS
Washington, D.C. 20231

SERIAL NUMBER	FILING DATE	FIRST NAMED APPLICANT	ATTORNEY DOCKET NO.

EXAMINER	
ART UNIT	PAPER NUMBER

DATE MAILED:

Please find below a communication from the EXAMINER in charge of this application

This application contains sequence disclosures that are encompassed by the definitions for nucleotide and/or amino acid sequences set forth in 37 CFR 1.821(a)(1) and (a)(2). Applicant must comply with the requirements of the sequence rules (37 CFR 1.821 - 1.825) before the application can be examined under 35 U.S.C. §§ 131 and 132.

A computer readable form (CRF) of the sequence listing was submitted. However, the CRF could not be processed by the Scientific and Technical Information Center (STIC) for the reason(s) set forth on the attached CRF Diskette Problem Report.

Applicant is given ONE MONTH, or THIRTY DAYS, whichever is longer, from the mailing date of this letter within which to comply with the sequence rules, 37 CFR 1.821 - 1.825. Failure to comply with these requirements will result in ABANDONMENT of the application under 37 CFR 1.821(g). Extensions of time may be obtained by filing a petition accompanied by the extension fee under the provisions of 37 CFR 1.136(a). In no case may an applicant extend the period for reply beyond the SIX MONTH statutory period. Direct the reply to the undersigned. Applicant is requested to return a copy of the attached CRF Diskette Problem Report with the reply.

Any inquiry concerning this communication should be directed to Examiner Ron Schwadron, Ph.D., Art Unit 1644, whose telephone number is (703) 308-4680. Any inquiry of a general nature or relating to the status of this application should be directed to the Technology Center receptionist whose telephone number is (703) 308-0196.

RONALD B. SCHWADRON
PRIMARY EXAMINER
GROUP 1800 1600

Ron Schwadron, Ph.D.
Art Unit 1644

Raw Sequence Listing Error Summary

ERROR DETECTED	SUGGESTED CORRECTION	SERIAL NUMBER: 09/350401
ATTN: NEW RULES CASES: PLEASE DISREGARD ENGLISH "ALPHA" HEADERS, WHICH WERE INSERTED BY P1		
1 _____ Wrapped Nucleics Wrapped Aminos	The number/text at the end of each line "wrapped" down to the next line. This may occur if your file was retrieved in a word processor after creating it. Please adjust your right margin to .3; this will prevent "wrapping."	
2 _____ Invalid Line Length	The rules require that a line not exceed 72 characters in length. This includes white spaces.	
3 _____ Misaligned Amino Numbering	The numbering under each 5' amino acid is misaligned. Do not use tab codes between numbers; use space characters, instead.	
4 _____ Non-ASCII	The submitted file was not saved in ASCII(DOS) text, as required by the Sequence Rules. Please ensure your subsequent submission is saved in ASCII text.	
5 _____ Variable Length	Sequence(s) _____ contain n's or Xaa's representing more than one residue. Per Sequence Rules, each n or Xaa can only represent a single residue. Please present the maximum number of each residue having variable length and indicate in the <220>-<223> section that some may be missing.	
6 _____ PatentIn 2.0 "bug"	A "bug" in PatentIn version 2.0 has caused the <220>-<223> section to be missing from amino acid sequences(s) _____. Normally, PatentIn would automatically generate this section from the previously coded nucleic acid sequence. Please manually copy the relevant <220>-<223> section to the subsequent amino acid sequence. This applies to the mandatory <220>-<223> sections for Artificial or Unknown sequences.	
7 _____ Skipped Sequences (OLD RULES)	Sequence(s) _____ missing. If intentional, please insert the following lines for each skipped sequence (2) INFORMATION FOR SEQ ID NO:X: (insert SEQ ID NO where "X" is shown) (i) SEQUENCE CHARACTERISTICS: (Do not insert any subheadings under this heading) (xi) SEQUENCE DESCRIPTION:SEQ ID NO:X: (insert SEQ ID NO where "X" is shown) This sequence is intentionally skipped Please also adjust the "(ii) NUMBER OF SEQUENCES:" response to include the skipped sequences.	
8 _____ Skipped Sequences (NEW RULES)	Sequence(s) _____ missing. If Intentional, please insert the following lines for each skipped sequence <210> sequence id number <400> sequence id number 000	
9 _____ Use of n's or Xaa's (NEW RULES)	Use of n's and/or Xaa's have been detected in the Sequence Listing. Per 1.823 of Sequence Rules, use of <220>-<223> is MANDATORY if n's or Xaa's are present. In <220> to <223> section, please explain location of n or Xaa, and which residue n or Xaa represents	
10 _____ Invalid <213> Response	Per 1.823 of Sequence Rules, the only valid <213> responses are: Unknown, Artificial Sequence, or scientific name (Genus/species). <220>-<223> section is required when <213> response is Unknown or Artificial Sequence	
11 _____ Use of <220>	Sequence(s) _____ missing the <220> "Feature" and associated numeric identifiers and responses. Use of <220> to <223> is MANDATORY if <213> "Organism" response is "Artificial Sequence" or "Unknown." Please explain source of genetic material in <220> to <223> section. (See "Federal Register," 06/01/1998, Vol. 63, No. 104, pp. 29631-32) (Sec. 1.823 of Sequence Rules	
12 _____ PatentIn 2.0 "bug"	Please do not use "Copy to Disk" function of PatentIn version 2.0. This causes a corrupted file, resulting in missing mandatory numeric identifiers and responses (as indicated on raw sequence listing). Instead, please use "File Manager" or any other manual means to copy file to floppy disk.	
13 _____ Misuse of n	n can only be used to represent a single nucleotide in a nucleic acid sequence. N is not used to represent any value not specifically a nucleotide.	

AMC/MH - Biotechnology Systems Branch - 08/21/2001

Input field 160 did not match output
See Enclosures/Attachments

1600

RAW SEQUENCE LISTING

PATENT APPLICATION: US/09/350,401

DATE: 09/27/2001

TIME: 14:19:41

Input Set : A:\139_10 SEQLIST.TXT

Output Set: N:\CRF3\09272001\I350401.raw

4 <110> APPLICANT: Alessandro Sette
5 John Sidney
6 Scott Southwood
7 Maria A. Vitiello
8 Brian D. Livingston
9 Esteban Celis
10 Ralph T. Kubo
11 Howard M. Grey
12 Robert Chesnut
14 <120> TITLE OF INVENTION: INDUCING CELLULAR IMMUNE RESPONSES TO
15 HEPATITIS B VIRUS USING PEPTIDE AND NUCLEIC ACID
16 COMPOSITIONS
18 <130> FILE REFERENCE: 139.10 US
20 <140> CURRENT APPLICATION NUMBER: US 09/350,401
21 <141> CURRENT FILING DATE: 1999-07-08
23 <150> PRIOR APPLICATION NUMBER: US 08/820,360
24 <151> PRIOR FILING DATE: 1997-03-12
26 <150> PRIOR APPLICATION NUMBER: US 60/013,363
27 <151> PRIOR FILING DATE: 1996-03-13
29 <150> PRIOR APPLICATION NUMBER: US 09/189,702
30 <151> PRIOR FILING DATE: 1998-11-10
32 <150> PRIOR APPLICATION NUMBER: US 08/205,713
33 <151> PRIOR FILING DATE: 1994-03-04
35 <150> PRIOR APPLICATION NUMBER: US 08/159,184
36 <151> PRIOR FILING DATE: 1993-11-29
38 <150> PRIOR APPLICATION NUMBER: US 08/073,205
39 <151> PRIOR FILING DATE: 1993-07-04
E--> 41 <160> NUMBER OF SEQ ID NOS: 3876 — Input 3876 Found 3877
43 <170> SOFTWARE: FastSEQ for Windows Version 4.0

ERRORED SEQUENCES

check diskette for actual contents MH

Does Not Comply
Corrected Diskette Needed

VERIFICATION SUMMARY

PATENT APPLICATION: US/09/350,401

DATE: 09/27/2001

TIME: 14:19:50

Input Set : A:\139_10 SEQLIST.TXT

Output Set: N:\CRF3\09272001\I350401.raw

L:15599 M:300 W: (50) Intentionally skipped Sequence, : Sequence Id (1197) SEQUENCE:
L:42602 M:341 W: (46) "n" or "Xaa" used, for SEQ ID#:3274
L:42619 M:341 W: (46) "n" or "Xaa" used, for SEQ ID#:3275
L:43130 M:341 W: (46) "n" or "Xaa" used, for SEQ ID#:3314
L:43147 M:341 W: (46) "n" or "Xaa" used, for SEQ ID#:3315
L:43164 M:341 W: (46) "n" or "Xaa" used, for SEQ ID#:3316
L:43181 M:341 W: (46) "n" or "Xaa" used, for SEQ ID#:3317
L:43198 M:341 W: (46) "n" or "Xaa" used, for SEQ ID#:3318
L:43215 M:341 W: (46) "n" or "Xaa" used, for SEQ ID#:3319
L:43232 M:341 W: (46) "n" or "Xaa" used, for SEQ ID#:3320
L:43249 M:341 W: (46) "n" or "Xaa" used, for SEQ ID#:3321
L:43266 M:341 W: (46) "n" or "Xaa" used, for SEQ ID#:3322
L:43283 M:341 W: (46) "n" or "Xaa" used, for SEQ ID#:3323
L:43300 M:341 W: (46) "n" or "Xaa" used, for SEQ ID#:3324
L:43317 M:341 W: (46) "n" or "Xaa" used, for SEQ ID#:3325
L:43334 M:341 W: (46) "n" or "Xaa" used, for SEQ ID#:3326
L:43351 M:341 W: (46) "n" or "Xaa" used, for SEQ ID#:3327
L:43368 M:341 W: (46) "n" or "Xaa" used, for SEQ ID#:3328
L:43385 M:341 W: (46) "n" or "Xaa" used, for SEQ ID#:3329
L:43402 M:341 W: (46) "n" or "Xaa" used, for SEQ ID#:3330
L:43419 M:341 W: (46) "n" or "Xaa" used, for SEQ ID#:3331
L:44073 M:341 W: (46) "n" or "Xaa" used, for SEQ ID#:3381
L:44090 M:341 W: (46) "n" or "Xaa" used, for SEQ ID#:3382
L:44536 M:341 W: (46) "n" or "Xaa" used, for SEQ ID#:3416
L:44553 M:341 W: (46) "n" or "Xaa" used, for SEQ ID#:3417
L:44572 M:341 W: (46) "n" or "Xaa" used, for SEQ ID#:3418
L:44589 M:341 W: (46) "n" or "Xaa" used, for SEQ ID#:3419
L:44606 M:341 W: (46) "n" or "Xaa" used, for SEQ ID#:3420
L:44623 M:341 W: (46) "n" or "Xaa" used, for SEQ ID#:3421
L:44640 M:341 W: (46) "n" or "Xaa" used, for SEQ ID#:3422
L:44657 M:341 W: (46) "n" or "Xaa" used, for SEQ ID#:3423
L:44674 M:341 W: (46) "n" or "Xaa" used, for SEQ ID#:3424
L:44691 M:341 W: (46) "n" or "Xaa" used, for SEQ ID#:3425
L:44708 M:341 W: (46) "n" or "Xaa" used, for SEQ ID#:3426
L:44725 M:341 W: (46) "n" or "Xaa" used, for SEQ ID#:3427
L:44742 M:341 W: (46) "n" or "Xaa" used, for SEQ ID#:3428
L:44759 M:341 W: (46) "n" or "Xaa" used, for SEQ ID#:3429
L:44776 M:341 W: (46) "n" or "Xaa" used, for SEQ ID#:3430
L:44793 M:341 W: (46) "n" or "Xaa" used, for SEQ ID#:3431
L:44810 M:341 W: (46) "n" or "Xaa" used, for SEQ ID#:3432
L:44827 M:341 W: (46) "n" or "Xaa" used, for SEQ ID#:3433
L:50630 M:341 W: (46) "n" or "Xaa" used, for SEQ ID#:3877
L:41 M:203 E: No. of Seq. differs, <160> Number Of Sequences:Input (3876) Counted (3877)

Attachment Printout
Explaining Errors

US/09/320401

<210> 3877
<211> 13
<212> PRT
<213> Artificial Sequence

Input: 3876 sequences
Found: 3877 sequences
Actual file contents as of

10/17/01

MH

<220>
<223> Artificial Peptide

<220>
<221> MOD_RES
<222> (3)
<223> Xaa = cyclohexylalanine, Phe or Tyr

<400> 3877
Ala Lys Xaa Val Trp Ala Asn Thr Leu Lys Ala Ala Ala
1 5 10

Does Not Comply
Corrected Diskette Needed

NOTICE TO COMPLY WITH REQUIREMENTS FOR PATENT APPLICATIONS CONTAINING NUCLEOTIDE SEQUENCE AND/OR AMINO ACID SEQUENCE DISCLOSURES

The nucleotide and/or amino acid sequence disclosure contained in this application does not comply with the requirements for such a disclosure as set forth in 37 C.F.R. 1.821 - 1.825 for the following reason(s):

- ☐ 1. This application clearly fails to comply with the requirements of 37 C.F.R. 1.821-1.825. Applicant's attention is directed to these regulations, published at 1114 OG 29, May 15, 1990 and at 55 FR 18230, May 1, 1990.
- ☐ 2. This application does not contain, as a separate part of the disclosure on paper copy, a "Sequence Listing" as required by 37 C.F.R. 1.821(c).
- ☐ 3. A copy of the "Sequence Listing" in computer readable form has not been submitted as required by 37 C.F.R. 1.821(e).
- ☒ 4. A copy of the "Sequence Listing" in computer readable form has been submitted. However, the content of the computer readable form does not comply with the requirements of 37 C.F.R. 1.822 and/or 1.823, as indicated on the attached copy of the marked -up "Raw Sequence Listing."
- ☐ 5. The computer readable form that has been filed with this application has been found to be damaged and/or unreadable as indicated on the attached CRF Diskette Problem Report. A Substitute computer readable form must be submitted as required by 37 C.F.R. 1.825(d).
- ☐ 6. The paper copy of the "Sequence Listing" is not the same as the computer readable form of the "Sequence Listing" as required by 37 C.F.R. 1.821(e).
- ☐ 7. Other: _____

Applicant Must Provide:

- ☒ An initial or substitute computer readable form (CRF) copy of the "Sequence Listing".
- ☒ An initial or substitute paper copy of the "Sequence Listing", as well as an amendment directing its entry into the specification.
- ☒ A statement that the content of the paper and computer readable copies are the same and, where applicable, include no new matter, as required by 37 C.F.R. 1.821(e) or 1.821(f) or 1.821(g) or 1.825(b) or 1.825(d).

For questions regarding compliance to these requirements, please contact:

For Rules Interpretation, call (703) 308-4216

For CRF Submission Help, call (703) 308-4212

For PatentIn software help, call (703) 308-6856

PLEASE RETURN A COPY OF THIS NOTICE WITH YOUR RESPONSE